Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ostrand-Rosenberg

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Cellular Immunology|June 1, 1990
Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous hostS Ostrand-Rosenberg, G A Cole, M I Nishimura, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2000
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gammaB A Pulaski, V K Clements, M R Pipeling, et al.
Seminars in Cancer Biology|October 1, 1991
Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejectionS Ostrand-Rosenberg, E P Garcia, C A Roby, et al.
Cancer Research|May 29, 2000
Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer modelB A Pulaski, D S Terman, S Khan, et al.
Cell Differentiation|December 1, 1984
Regulation of major histocompatibility gene expression in teratocarcinoma 402AX cellsS Ostrand-Rosenberg, V Clements, G Cole, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory moleculesS Baskar, V K Clements, L H Glimcher, et al.
International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine|February 1, 1988
Endogenous superoxide dismutase and catalase activities and radiation resistance in mouse cell linesC A Davy, Z Tesfay, J Jones, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1997
Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunityT D Armstrong, V K Clements, B K Martin, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1987
Allogeneic H-2 antigen expression is insufficient for tumor rejectionG A Cole, G A Cole, V K Clements, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 1993
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II moleculesS Baskar, S Ostrand-Rosenberg, N Nabavi, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cellular Immunology|June 1, 1990
Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous hostS Ostrand-Rosenberg, G A Cole, M I Nishimura, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2000
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gammaB A Pulaski, V K Clements, M R Pipeling, et al.
Seminars in Cancer Biology|October 1, 1991
Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejectionS Ostrand-Rosenberg, E P Garcia, C A Roby, et al.
Cancer Research|May 29, 2000
Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer modelB A Pulaski, D S Terman, S Khan, et al.
Cell Differentiation|December 1, 1984
Regulation of major histocompatibility gene expression in teratocarcinoma 402AX cellsS Ostrand-Rosenberg, V Clements, G Cole, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory moleculesS Baskar, V K Clements, L H Glimcher, et al.
International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine|February 1, 1988
Endogenous superoxide dismutase and catalase activities and radiation resistance in mouse cell linesC A Davy, Z Tesfay, J Jones, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1997
Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunityT D Armstrong, V K Clements, B K Martin, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1987
Allogeneic H-2 antigen expression is insufficient for tumor rejectionG A Cole, G A Cole, V K Clements, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 1993
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II moleculesS Baskar, S Ostrand-Rosenberg, N Nabavi, et al.
Pageof 6